Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with vasomotor symptoms with a uterus who are postmenopausal or in late menopause transition~* Body Mass Index (BMI) \<36 kg/m2~* Class I-III mammogram within 6 months of Random Periareolar Fine Needle Aspiration (RPFNA); If Class 0 or 4, must be resolved with additional procedures~* If previously on oral contraceptives or hormone replacement, off for 8 weeks or more prior to baseline RPFNA; the exception is low dose vaginal hormones~* Confirmed moderate risk of developing breast cancer~* RPFNA results within study defined range~* Kidney and liver function within study defined range~* Willing and able to comply with study related procedures~Exclusion Criteria:~* Previous biopsy showing evidence of breast cancer~* Have a predisposition to or prior history of thromboembolism, deep venous thrombosis, pulmonary embolism, or stroke~* History of renal or liver disease~* Prior ovarian or endometrial cancer~* Stopped or started hormone replacement within 8 weeks~* Any other condition or intercurrent illness that in the opinion of the investigator makes the woman a poor candidate for RPFNA~* Currently taking or have taken specific medications in the past 6 months~* Participation on any chemoprevention trial within 6 months~* Current illness which would make potential participant unsuitable for enrollment

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 61 Years
- Healthy Volunteers: f

Study Arms:
- Duavee (Type: EXPERIMENTAL): Participants will be asked to take Duavee for 6 months while on the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).